Clinical Trials · NCT03144271
Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 58
- Start date
- Jun 2007
- Locations
- 1 site, Germany
- Primary endpoint
- Number of Adverse Events